Nusinersen Sodium Patent Expiration

Nusinersen Sodium is Used for treating spinal muscular atrophy in infants and adults by increasing exon-7 inclusion in SMN2 mRNA. It was first introduced by Biogen Idec Inc in its drug Spinraza on Dec 23, 2016.


Nusinersen Sodium Patents

Given below is the list of patents protecting Nusinersen Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Spinraza US12013403 Compositions and methods for detection of SMN protein in a subject and treatment of a subject Mar 04, 2036 Biogen Idec
Spinraza US10436802 Methods for treating spinal muscular atrophy Sep 11, 2035 Biogen Idec
Spinraza US9926559 Compositions and methods for modulation of SMN2 splicing in a subject Jan 09, 2034 Biogen Idec
Spinraza US8361977 Compositions and methods for modulation of SMN2 splicing Dec 23, 2030 Biogen Idec
Spinraza US8980853 Compositions and methods for modulation of SMN2 splicing in a subject Nov 24, 2030 Biogen Idec
Spinraza US9717750 Compositions and methods for modulation of SMN2 splicing in a subject Jun 17, 2030 Biogen Idec
Spinraza US7838657 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Jul 11, 2027 Biogen Idec
Spinraza US10266822 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Dec 05, 2025 Biogen Idec
Spinraza US8110560 Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Dec 05, 2025 Biogen Idec
Spinraza US7101993 Oligonucleotides containing 2′-O-modified purines Sep 05, 2023

(Expired)

Biogen Idec
Spinraza US6210892 Alteration of cellular behavior by antisense modulation of mRNA processing Oct 07, 2018

(Expired)

Biogen Idec
Spinraza US6166197 Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions Dec 26, 2017

(Expired)

Biogen Idec



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nusinersen Sodium's patents.

Given below is the list recent legal activities going on the following patents of Nusinersen Sodium.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 19 Jun, 2024 US8361977
Email Notification 21 Mar, 2024 US9717750
Change in Power of Attorney (May Include Associate POA) 21 Mar, 2024 US9717750
Patent Term Extension Certificate 18 Mar, 2024 US8361977
Change in Power of Attorney (May Include Associate POA) 11 Mar, 2024 US8361977
Email Notification 11 Mar, 2024 US8361977
Resp. to req. for info. sent under 37 CFR 1.750 05 Mar, 2024 US8361977
Change in Power of Attorney (May Include Associate POA) 29 Feb, 2024 US10436802
Email Notification 29 Feb, 2024 US10436802
Change in Power of Attorney (May Include Associate POA) 29 Feb, 2024 US9926559


Nusinersen Sodium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List